CSNK1A1 and prostate cancer: The efficacy of lenalidomide-induced CK1α degradation in other cell lines, including THP-1 monocytes, HCT116 colorectal cancer, A549 lung adenocarcinoma, DLD-1 colorectal cancer, PC-3 prostate cancer, and HaCaT keratinocyte cell lines were more variable with the most substantial CK1α degradation observed in HCT116, DLD-1, and HaCaT cells (Fig 1B).